医学
不利影响
乳腺癌
叙述性评论
癌症
临床试验
转移性乳腺癌
生活质量(医疗保健)
入射(几何)
肿瘤科
内科学
重症监护医学
物理
护理部
光学
作者
Oraianthi Fiste,Evangelos Mavrothalassitis,Kleoniki Apostolidou,Chrysanthi O Trika,Michalis Liontos,Konstantinos Koutsoukos,Maria Kaparelou,Constantine Dimitrakakis,Maria Gavriatopoulou,Meletios A. Dimopoulos,Flora Zagouri
标识
DOI:10.1016/j.critrevonc.2024.104296
摘要
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have unprecedentedly advanced hormone-dependent breast cancer treatment paradigm. In the metastatic setting, ribociclib has consistently demonstrated survival benefit in pre-, peri-, and postmenopausal patients, conjugating efficacy with health-related quality of life preservation. Accordingly, the emergence of cardiac and/or vascular adverse events related to this novel targeted agent is gaining significant interest. This narrative review provides an overview of the incidence and spectrum of cardiovascular toxicity, in both clinical trial framework and real-world evidence. The potential pathogenetic mechanism, along with the available diagnostic parameters including biomarkers, and proper management, are also summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI